Uncategorized
Rituximab used to treat recalcitrant noninfectious scleritis
Infusion therapy with rituximab in patients with refractory noninfectious scleritis was successful, according to a retrospective case series with a mean follow-up of 34 months.In total, 14 of 15 patients (93.3%) demonstrated a clinical improvement with systemic infusion of Rituxan (rituximab, Genentech), and 13 of 15 patients (86.7%) achieved a scleritis activity score of zero at 6 months.